Featured Clinical Trials

  • IRB #19017: A phase 1/2 trial of pembrolizumab in combination with blinatumomab in patients with relapsed/refractory acute lymphoblastic leukemia. PI: Elizabeth Budde
  • IRB #191017: Phase 1b trial of pembrolizumab, decitabine +/- venetoclax combination therapy in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndrome. PI: Guido Marcucci 
  • IRB #20472: PI: A phase 2 study to evaluate the anti-tumor activity of single agent flotetuzumab in advanced CD123-positive hematological malignancies. PI: Ibrahim Aldoss 
  • IRB #21134: A phase1 study combining venetoclax with a pediatric-inspired regimen for newly diagnosed adults with B cell Ph-like acute lymphoblastic leukemia. PI: Ibrahim Aldoss 
  • IRB #21380: A Phase 1 Trial of 8-Chloro-Adenosine in Combination with Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia.. PI: Vinod Pullarkat 
  • IRB #21751: Phase 1b Study of IDH Inhibition with Enasidenib and MEK Inhibition with Cobimetinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia who have Co-occurring IDH2 and RAS Signaling Gene Mutations. PI: Brian Ball 
  • IRB #22178: Phase 1 Trial of Navitoclax/Venetoclax/Decitabine Combination Therapy in Relapsed/Refractory Acute Myeloid Leukemia. PI: Guido Marcucci